Background
Broadly neutralizing antibodies (bNAbs) can suppress diverse HIV strains and are being explored for long-term protection. Although our lab has demonstrated that long-term expression of AAV-delivered bNAbs can lead to a functional cure, persistent viral reservoirs are still detectable for many years. To better target this reservoir, we evaluated the deliverability and antiviral potential of bNAbs engineered for 80-100-fold enhanced antibody-dependent cellular cytotoxicity (ADCC).
Methods
Six rhesus macaques chronically infected with SHIV-AD8 received passive infusions of 3BNC117 and 10-1074 (30 mg/kg every 3 weeks). Three controls received wildtype bNAbs, while three animals received glycoengineered variants with Fc receptor mutations previously shown to enhance ADCC 80–100-fold. Viral loads, serum antibody levels, anti-drug antibody (ADA) responses, and reservoir size were monitored. Animals will be followed for 45 weeks total (study ongoing).
Results
Macaques were infected with SHIV-AD8 15 weeks prior to infusion. Wildtype bNAbs achieved serum concentrations of 70-200 μg/ml 10-1074 and 5-14 μg/ml 3BNC117 without detectable ADA. In contrast, ADCC-enhanced variants were rapidly cleared, with transient levels detectable only 1-week post-infusion. For 3BNC117, these levels remained under 1ug/ml. While ADA responses were low compared with those commonly observed with AAV delivery, detectable ADA levels were observed against the ADCC-enhanced 3BNC117 (O.D. 0.2-0.4). Infusion-related reactions occurred in all 3 macaques receiving ADCC-enhanced bNAbs and required diphenhydramine and dexamethasone premedication. Viral suppression was durable in wildtype recipients but inconsistent and fluctuating in ADCC-enhanced animals.
Conclusions
ADCC enhancement increased infusion-related toxicity and accelerated bNAb clearance, preventing durable viral suppression. These effects likely reflect strong FcγRIIIa activation, as reactions occurred even after the first infusion. In contrast, wildtype bNAbs achieved stable serum levels and consistent suppression. Wildtype bNAbs suppressed viral loads 1 week following their first infusion with blips only observed with animal r22097. While Fc engineering remains promising for reservoir clearance, moderate ADCC enhancement may maximize therapeutic efficacy.